FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225724116> ?p ?o ?g. }

• W4225724116 endingPage "e666" @default.
• W4225724116 startingPage "e666" @default.
• W4225724116 abstract "Tafasitamab is a humanized monoclonal antibody that binds to the CD19 antigen, which is expressed in tumor cells from patients with diffuse large B-cell lymphoma (DLBCL). On June 24, 2021, a positive opinion for a conditional marketing authorization was issued by the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) for tafasitamab, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory DLBCL who are ineligible for autologous stem cell transplantation. Tafasitamab was evaluated in the phase 2 single-arm, multicenter, open-label L-MIND clinical trial. The primary endpoint of this trial was objective response rate (ORR). The best ORR, achieved at any time during the study, was 56.8% (95% confidence interval: 45.3%-67.8%), and the median duration of response was 34.6 months (95% confidence interval: 26.1-not reached). The most frequently reported adverse events by system organ class were infections and infestations (72.8%; grade ≥3: 29.6%), blood and lymphatic system disorders (65.4%; grade ≥3: 56.8%), gastrointestinal disorders (64.2%; grade ≥3: 2.5%), and general disorders and administration site conditions (58.0%; grade ≥3: 8.6%). The aim of this article is to summarize the scientific review of the application which led to the positive opinion by the CHMP." @default.
• W4225724116 created "2022-05-05" @default.
• W4225724116 creator A5010253261 @default.
• W4225724116 creator A5014405902 @default.
• W4225724116 creator A5016513114 @default.
• W4225724116 creator A5017364811 @default.
• W4225724116 creator A5021370006 @default.
• W4225724116 creator A5045198992 @default.
• W4225724116 creator A5086256947 @default.
• W4225724116 creator A5086620890 @default.
• W4225724116 date "2021-11-18" @default.
• W4225724116 modified "2023-10-18" @default.
• W4225724116 title "The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma" @default.
• W4225724116 cites W1967008538 @default.
• W4225724116 cites W1992950983 @default.
• W4225724116 cites W2018071905 @default.
• W4225724116 cites W2026374501 @default.
• W4225724116 cites W2084433006 @default.
• W4225724116 cites W2095308469 @default.
• W4225724116 cites W2107894877 @default.
• W4225724116 cites W2109440389 @default.
• W4225724116 cites W2132611552 @default.
• W4225724116 cites W2136060045 @default.
• W4225724116 cites W2150587745 @default.
• W4225724116 cites W2525478941 @default.
• W4225724116 cites W2560592054 @default.
• W4225724116 cites W2593288957 @default.
• W4225724116 cites W2605009867 @default.
• W4225724116 cites W2744261860 @default.
• W4225724116 cites W2773804840 @default.
• W4225724116 cites W2792232222 @default.
• W4225724116 cites W2903062212 @default.
• W4225724116 cites W2984927918 @default.
• W4225724116 cites W3034162969 @default.
• W4225724116 cites W3083741488 @default.
• W4225724116 cites W4205736005 @default.
• W4225724116 doi "https://doi.org/10.1097/hs9.0000000000000666" @default.
• W4225724116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34805769" @default.
• W4225724116 hasPublicationYear "2021" @default.
• W4225724116 type Work @default.
• W4225724116 citedByCount "0" @default.
• W4225724116 crossrefType "journal-article" @default.
• W4225724116 hasAuthorship W4225724116A5010253261 @default.
• W4225724116 hasAuthorship W4225724116A5014405902 @default.
• W4225724116 hasAuthorship W4225724116A5016513114 @default.
• W4225724116 hasAuthorship W4225724116A5017364811 @default.
• W4225724116 hasAuthorship W4225724116A5021370006 @default.
• W4225724116 hasAuthorship W4225724116A5045198992 @default.
• W4225724116 hasAuthorship W4225724116A5086256947 @default.
• W4225724116 hasAuthorship W4225724116A5086620890 @default.
• W4225724116 hasBestOaLocation W42257241161 @default.
• W4225724116 hasConcept C121332964 @default.
• W4225724116 hasConcept C126322002 @default.
• W4225724116 hasConcept C142424586 @default.
• W4225724116 hasConcept C143998085 @default.
• W4225724116 hasConcept C197934379 @default.
• W4225724116 hasConcept C203092338 @default.
• W4225724116 hasConcept C2776063141 @default.
• W4225724116 hasConcept C2776364478 @default.
• W4225724116 hasConcept C2778524551 @default.
• W4225724116 hasConcept C2779338263 @default.
• W4225724116 hasConcept C2911091166 @default.
• W4225724116 hasConcept C535046627 @default.
• W4225724116 hasConcept C71924100 @default.
• W4225724116 hasConcept C87355193 @default.
• W4225724116 hasConceptScore W4225724116C121332964 @default.
• W4225724116 hasConceptScore W4225724116C126322002 @default.
• W4225724116 hasConceptScore W4225724116C142424586 @default.
• W4225724116 hasConceptScore W4225724116C143998085 @default.
• W4225724116 hasConceptScore W4225724116C197934379 @default.
• W4225724116 hasConceptScore W4225724116C203092338 @default.
• W4225724116 hasConceptScore W4225724116C2776063141 @default.
• W4225724116 hasConceptScore W4225724116C2776364478 @default.
• W4225724116 hasConceptScore W4225724116C2778524551 @default.
• W4225724116 hasConceptScore W4225724116C2779338263 @default.
• W4225724116 hasConceptScore W4225724116C2911091166 @default.
• W4225724116 hasConceptScore W4225724116C535046627 @default.
• W4225724116 hasConceptScore W4225724116C71924100 @default.
• W4225724116 hasConceptScore W4225724116C87355193 @default.
• W4225724116 hasIssue "12" @default.
• W4225724116 hasLocation W42257241161 @default.
• W4225724116 hasLocation W42257241162 @default.
• W4225724116 hasLocation W42257241163 @default.
• W4225724116 hasLocation W42257241164 @default.
• W4225724116 hasLocation W42257241165 @default.
• W4225724116 hasOpenAccess W4225724116 @default.
• W4225724116 hasPrimaryLocation W42257241161 @default.
• W4225724116 hasRelatedWork W2021159149 @default.
• W4225724116 hasRelatedWork W2039196526 @default.
• W4225724116 hasRelatedWork W2059075557 @default.
• W4225724116 hasRelatedWork W2061838129 @default.
• W4225724116 hasRelatedWork W2314027618 @default.
• W4225724116 hasRelatedWork W2336872381 @default.
• W4225724116 hasRelatedWork W2576841436 @default.
• W4225724116 hasRelatedWork W2890410648 @default.
• W4225724116 hasRelatedWork W2980591007 @default.
• W4225724116 hasRelatedWork W3016752922 @default.
• W4225724116 hasVolume "5" @default.

• next